The purpose of this study is to evaluate the level of satisfaction experienced by asthma or chronic obstructive pulmonary disease (COPD) patients when using the Fluticasone/Salmeterol HFA Metered Dose Inhaler (MDI) with counter, as compared to using Fluticasone/Salmeterol HFA MDI without counter.

Inclusion Criteria:

• Outpatient
• Documented physician diagnosis of asthma or COPD
• Requires use of a controller and long acting beta 2 agonist
• Ability to provided written informed consent

Exclusion Criteria:

• Patients with life threatening asthma or COPD
• Historical or current evidence of significant diseases
• Immediate or delayed hypersensitivity to inhaled short acting beta2agonist or sympathomimetic drug or any component of the MDI formulation
• History of drug or alcohol abuse Abnormal chest x ray not consistent with asthma or COPD
• Use of supplemental oxygen; systemic corticosteroids; short acting beta2agonists other than VENTOLIN HFA; antibiotics for respiratory infections; anti-arrhythmics; anticonvulsants; central nervous system stimulants; tricyclic antidepressants and monoamine oxidase inhibitors.